放疗后手术治疗恶性胸膜间皮瘤(SMART):单中心二期试验最终结果
这项单中心二期试验评估了SMART方案(短程加速高剂量半胸IMRT后行胸膜外全肺切除术)的可行性,共治疗96例可切除的初治恶性胸膜间皮瘤患者。主要终点为30天围手术期治疗相关死亡或并发症,结果显示49%患者发生3-4级事件,1%发生5级事件;
要点
- SMART方案在初治可切除恶性胸膜间皮瘤中可行,但围手术期3-4级事件发生率较高。
- 常见首次复发部位为对侧胸腔和腹膜腔。
核心结论
- 放疗后行胸膜外全肺切除术可获得良好的早期和长期结果。
- 减少方案中4级事件在技术上要求高,可能影响术后生存。
研究设计与样本
- 单中心、二期试验,纳入96例符合条件的初治、组织学证实、可切除cT1-3N0M0恶性胸膜间皮瘤患者。
- 患者接受25 Gy/5次/1周半胸IMRT(高危区同步加量5 Gy),1周内行胸膜外全肺切除术,ypN+者接受辅助化疗。
- 主要终点为可行性(30天围手术期治疗相关死亡或3-4级并发症),最终分析基于意向治疗。
主要发现
- 47例(49%)患者发生30天围手术期3-4级事件,1例(1%)患者围手术期30天内死亡(5级事件,肺炎)。
- 最常见的首次复发部位为对侧胸腔(72例中33例,46%)和腹膜腔(72例中32例,44%)。
临床怎么用
- SMART方案可作为初治可切除恶性胸膜间皮瘤的一种可行治疗选择。
- 需关注围手术期3-4级事件,尤其是4级事件的管理可能影响长期生存。
局限性
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical feasibility of the SMART protocol. METHODS: In this single-centre, phase 2 trial, patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, with histologically proven, resectable, cT1-3N0M0 disease who had previously untreated malignant pleural mesothelioma were eligible for inclusion. Patients received 25 Gy in five daily fractions over 1 week to the entire ipsilateral hemithorax with a concomitant 5 Gy boost to high risk areas followed by extrapleural pneumonectomy within 1 week. Adjuvant chemotherapy was offered to patients with ypN+ disease on final pathology. The primary endpoint was feasibility, which was defined as the number of patients with 30-day perioperative treatment-related death (grade 5 events) or morbidity (grade 3 or 4 events). A key secondary endpoint was cumulative incidence of distant recurrence. The final analysis was done on an intention-to-treat basis (including all eligible patients). This trial is registered with ClinicalTrials.gov, NCT00797719. FINDINGS: Between Nov 1, 2008, and Oct 31, 2019, 102 patients were enrolled onto the trial and 96 eligible patients were treated with SMART on protocol and included in the analysis. Extrapleural pneumonectomy was done at a median of 5 days (range 2-12) after completing IMRT. 47 (49%) patients had 30-day perioperative grade 3-4 events and one (1%) patient died within 30 days perioperatively (grade 5 event; pneumonia). After a median follow-up of 46·8 months (IQR 13·4-61·2), the 5-year cumulative incidence of distant recurrence was 62 (63·3% [95% CI 52·3-74·4]). The most common first sites of recurrence were the contralateral chest (33 [46%] of 72 patients) and the peritoneal cavity (32 [44%]). INTERPRETATION: Results from this study suggest that extrapleural pneumonectomy after radiotherapy can be done with good early and long-term results. However, minimising grade 4 events on the protocol is technically demanding and might affect survival beyond the post-operative period. FUNDING: Princess Margaret Hospital Foundation Mesothelioma Research Fund.
引用
- Cho BCJ, Donahoe L, Bradbury PA, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021. PMID: 33450184. doi:10.1016/S1470-2045(20)30606-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。